Company intelligence / Profile preview

REGENXBIO Inc.

Rockville, Maryland, United States of Americaregenxbio.com ↗

Ownership: Public · RGNX
Employees: ~353
Development stage: Phase 3

Overview

REGENXBIO has multiple clinical programs showing promising results. RGX-202 for Duchenne has demonstrated robust microdystrophin expression with good tolerability. RGX-121 for MPS II has advanced to BLA filing. ABBV-RGX-314 for wet AMD is progressing toward global regulatory submissions.

Therapeutic areas: OphthalmologyImmunologyRare DiseasesNeurology
Modalities: Gene therapyAAV-mediated antibody delivery
Industry: Biotech

Drug pipeline

12 assets

surabgene lomparvovec

11 more assets in the full pipeline.

Request access →

Partnerships

AbbVie (eye care collaboration)Nippon Shinyaku Co., Ltd. (for RGX-121 and RGX-111)Neurimmune (for neurodegenerative diseases)Ultragenyx Pharmaceutical Inc.

Financials

Market cap: $445.9M
Total revenue: $89M
Enterprise value: $257.9M

Beyond the preview

Go deeper on REGENXBIO Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGENXBIO Inc..

Explore the full profile